Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis

Cardiol Therapeutics has enrolled 110 patients in its MAVERIC Phase III trial ahead of schedule, with results expected in mid-2027, delayed from the previous Q1 2027 guidance. The trial aims to evaluate the efficacy of CardiolRx in reducing recurrence of pericarditis, with a primary analysis focused on the time to the first new episode. The company plans to expand enrollment to ensure sufficient event count for robust statistical power, supported by a cash runway extending into Q1 2028.